High Dose Botox Injection for Patients with Internal Anal Sphincter Achalasia Persistent to Posterior Internal Anal Sphincter Myectomy
Iranian Journal of Pediatric Surgery,
Vol. 6 No. 2 (2020),
7 December 2020
,
Page 66-73
https://doi.org/10.22037/irjps.v6i2.31946
Abstract
Introduction: one of the most common reported chief complaints in visits to pediatricians is constipation. Although in a majority of cases with no anatomical defect, dietary manipulation, stool softeners, and oral laxatives are successful, some patients fail to respond.
Internal Anal Sphincter (IAS) Achalasia is one of the causes of constipation.It results in failure of IAS relaxation and has similar clinical presentation to Hirschsprung’s disease with absence of rectosphincteric inhibitory reflex on anorectal manometry (ARM) and presence of ganglion cells on rectal biopsy.
Although posterior internal anal sphincter myectomy (ISM) is considered the standard treatment for IASA, some cases fail to respond and present with intractable constipation which may be associated with soiling.
This research aims to assess the role of botox injection for treatment of patients who presented with intractable constipation and have already beentreated by posterior IAS myectomy.
Materials and Methods:Internal anal sphincter Botox injection was performed (with a dose of 20 U/Kg) in 14 patients with internal anal sphincter achalasia (IASA); who had presented with intractable constipationafter being treated by posterior internal anal sphincter myectomy. Patients were followed for 2 years after injection.
Result: of all 14 patients with persistent constipation (resistant to oral laxatives), 12 patients (85.7%) had regular bowel function for more than 6 months after botox injection therapy (P < 0.05).
Of all 14 patients that had needed rectal enema for defecation, no patient needed rectal enema after botox injection therapy (P < 0.05). Of 5 patients with fecal soiling before botox injection therapy (4 had occasionalsoiling, and 1 had soiling every day without social problems) only a single patient experienced transient fecal soiling for 2 weeks after botox injection therapy (P < 0.05).
No patient needed another botox injection in 2 years of follow up.
Conclusion: IAS Botox injection therapy (BIT) was successfully used to manage IASA patients who had presented with intractable constipation after posterior myectomy. This method significantly reduces the need for laxatives and rectal enema; and improves constipation, fecal soiling and bowel movements at the same time.
- internal anal sphincter
- achalasia
- constipation
- myectomy
- botulinum toxin
- Hirschsprung’s disease
How to Cite
References
Keshtgar AS, Ward HC, Clayden GS, editors: Diagnosis and management of children with intractable constipation. Seminars in pediatric surgery; 2004.
Taitz L, Wales J, Urwin O, et al: Factors associated with outcome in management of defecation disorders. Archives of Disease in Childhood 1986;61(5):472-7.
Loening-Baucke V: Constipation in early childhood: patient characteristics, treatment, and longterm follow up. Gut 1993;34(10):1400-4.
Fitzgerald JF: Constipation in children. Pediatrics in review 1987;8(10):299-302.
Eltayeb AA, Ibrahim NH, Moeen SM, et al: The use of botulinum toxin in children with chronic constipation. International Surgery Journal 2017;4(6):1845-9.
Hurst AF: Anal achalasia and megacolon (Hirschsprung’s disease: idiopathic dilatation of the colon. Guys Hosp Rep 1934;84:317-50.
Foroutan HR, Hosseini S, Banani SA, et al:Comparison of botulinium toxin injection and posterior anorectal myectomy in treatment of internal anal sphincter achalasia. Indian J Gastroenterol 2008;27(02):62-5.
De Caluwe D, Yoneda A, Akl U, et al: Internal anal sphincter achalasia: outcome after internal sphincter myectomy. Journal of pediatric surgery
;36(5):736-8.
Messineo A, Codrich D, Monai M, et al: The treatment of internal anal sphincter achalasia with botulinum toxin. Pediatric surgery international 2001;17(7):521-3.
Puri P: Variant Hirschsprung's disease. Journal of pediatric surgery 1997;32(2):149-57.
Friedmacher F, Puri P: Comparison of posterior internal anal sphincter myectomy and intrasphincteric botulinum toxin injection for treatment of internal anal sphincter achalasia: a meta-analysis. Pediatric surgery international 2012;28(8):765-71.
Langer JC, Birnbaum E: Preliminary experience with intrasphincteric botulinum toxin for persistent constipation after pull-through for Hirschsprung's disease. Journal of pediatric surgery 1997;32(7):1059-62.
Irani K, Rodriguez L, Doody DP, et al: Botulinum toxin for the treatment of chronic constipation in children with internal anal sphincter dysfunction. Pediatric surgery international 2008;24(7):779-83.
Doodnath R, Puri P: Long-term outcome of internal sphincter myectomy in patients with internal anal sphincter achalasia. Pediatric surgery international 2009;25(10):869-71.
Kobayashi H, Hirakawa H, Puri P: Abnormal internal anal sphincter innervation in patients with Hirschsprung's disease and allied disorders. Journal of pediatric surgery 1996;31(6):794-9.
Ciamarra P, Nurko S, Barksdale E, et al: Internal anal sphincter achalasia in children: clinical characteristics and treatment with Clostridium botulinum toxin. J Pediatr Gastr Nutr2003;37(3):315-9.
Oue T, Puri P: Altered intramuscular innervation and synapse formation in internal sphincter achalasia. Pediatric surgery international 1999;15(3-4):192-4.
Valtorta F, Lezzi N, Benfenati F, et al: Accelerated structural maturation induced by synapsin I at developing neuromuscular synapses of Xenopus laevis. European Journal of Neuroscience 1995;7(2):261-70.
Hirakawa H, Kobayashi H, O'Briain DS, et al: Absence of NADPH-diaphorase activity in internal anal sphincter (IAS) achalasia. Journal of pediatric gastroenterology and nutrition1995;20(1):54-8.
Hoogerwerf WA, Pasricha PJ: Botulinum toxin for spastic gastrointestinal disorders. Best Practice & Research Clinical Gastroenterology 1999;13(1):131-43.
Monheit GD, Pickett A: AbobotulinumtoxinA: a 25-year history. Aesthetic surgery journal 2017;37(suppl_1):S4-S11.
Carter D, Dickman R: The role of Botox in colorectal disorders. Current treatment options in gastroenterology 2018;16(4):541-7.
Liu J-Y, Zheng Z-Q, Zhao K, et al: Treatment of Adult Hirschsprung's Disease by Botulinum Toxin A through Anorectal Injection. Chinese Med J-Peking 2018;131(24):3007.
- Abstract Viewed: 760 times
- PDF Downloaded: 230 times